AlphAIalphai — Financial news for AI agents
SEC EDGARJUL 72 min read$ANIP

CAREY STEPHEN P. sold $285K of ANIP

CAREY STEPHEN P. (SVP & CFO) sold 3,313 shares of ANI PHARMACEUTICALS INC (ANIP) at $86.00 ($0.28M total) on 2026-07-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · CAREY STEPHEN P.
Published Jul 7, 2026, 1:40 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 7, 2026, 2:02 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$ANIP
Neutral
medium confidence
Mentioned
$ANIP
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ANIPNeutralLow
01

Why it matters

An SVP & CFO sold $284,918 worth of shares via an open-market sale under a pre-arranged 10b5-1 plan; no other company fundamentals are disclosed.

02

Market read

Traders may monitor for patterns in insider activity, but this specific filing alone is unlikely to drive a major repricing.

03

What to watch

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it reduces the informational content versus discretionary selling.

Relevance 3/10Novelty 3/10Timing: SEC Form 4 filed July 6 for a July 2 insider sale.

Background

The article is an SEC Form 4 insider transaction disclosure for ANI Pharmaceuticals (ANIP).

Company-level read

Ticker impact

$ANIPNeutralMedium confidence
Context

ANI Pharmaceuticals disclosed an SVP & CFO open-market sale of 3,313 shares at $86 on a pre-arranged 10b5-1 plan.

Expected impact

Likely limited near-term impact; any reaction should be muted unless paired with other new company-specific catalysts.

Evidence & confidence

Form 4 shows a planned open-market sale with no accompanying guidance, operational update, or transaction tied to a corporate event.

Market effects

Sector

Minimal—this is company-specific insider transaction data with no sector-wide regulatory/clinical/financing signal.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Some traders may read repeated insider selling as a bearish signal, especially if it coincides with other negative developments not mentioned here.

Key entities

  • issuer
    ANI Pharmaceuticals Inc

    Subject of the Form 4 insider transaction disclosure.

  • insider
    Carey Stephen P.

    SVP & CFO who executed the open-market sale.

Read at source← All news

Related articles

AUG 7
$ANIPMed

ANI Pharmaceuticals revenue rises 25.9% to $266M

ANI Pharmaceuticals reported record Q2 2026 net revenue of $266.0 million, up 25.9% year over year. GAAP net income was $24.7 million and adjusted EBITDA rose 32.4% to $71.6 million. Cortrophin Gel revenue grew 43.5% to $117.1 million, but full-year Cortrophin guidance was cut to $520–$540 million. ANIP shares fell 5.53% to $78.06.

grafa.com3 min
AUG 7
$ANIPMed

ANI Pharmaceuticals Inc (ANIP) (Q2 2026) Earnings Call Highlights: Record Revenue

ANI Pharmaceuticals’ Q2 2026 earnings call covered Cortrophin Gel gout expansion and guidance. CEO Nikhil Alwani said sales force reps expanded to 180 by end-June, with over 95% generating multiple patient cases. Full-year Cortrophin guidance was trimmed to $520-$540 million, citing first-half performance and factors beyond case counts. Operating leverage investment is expected to drive improved margins in 2027.

finance.yahoo.com4 min
AUG 7
$ANIPMed

ANI PHARMACEUTICALS INC (ANIP): Results of Operations and Financial Condition

ANI PHARMACEUTICALS INC (ANIP) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 anip-20260807xexx991.htm EX-99.1 Document Exhibit 99.1 ANI Pharmaceuticals Reports Record Second Quarter 2026 Financial Results • Quarterly net revenues of $266.0 million, an increase of 25.9% year-over-year • Purified Cortrophin ® Gel net revenues of $117.1 million, an

SEC EDGAR 8-K6 min